FILING ANALYSIS · THURSDAY, NOVEMBER 12
SUTRO BIOPHARMA, INC. STRO — 8-K: Results of Operations and Financial Condition
neutral
Sutro Biopharma reported a strong balance sheet with $142.2 million in cash and provided updates on its pipeline, including the advancement of STRO-004 and STRO-006, but no quantified surprises were disclosed in the filing.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →